These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438 [TBL] [Abstract][Full Text] [Related]
3. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Witjes JA; Douglass J Nat Clin Pract Urol; 2007 Oct; 4(10):542-9. PubMed ID: 17921969 [TBL] [Abstract][Full Text] [Related]
4. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681 [TBL] [Abstract][Full Text] [Related]
5. Recent developments in fluorescence cystoscopy: do novel agents bring a benefit? Schmidbauer J; Marberger M Curr Opin Urol; 2007 Sep; 17(5):347-51. PubMed ID: 17762629 [TBL] [Abstract][Full Text] [Related]
6. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance. Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730 [TBL] [Abstract][Full Text] [Related]
7. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887 [TBL] [Abstract][Full Text] [Related]
8. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971 [TBL] [Abstract][Full Text] [Related]
9. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ; J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283 [TBL] [Abstract][Full Text] [Related]
10. Fluorescence cystoscopy: is it ready for use in routine clinical practice? Spiess PE; Grossman HB Curr Opin Urol; 2006 Sep; 16(5):372-6. PubMed ID: 16905985 [TBL] [Abstract][Full Text] [Related]
11. [Fluorescence diagnosis and photodynamic therapy in urology]. Stepp H; Waidelich R Aktuelle Urol; 2007 Nov; 38(6):455-64. PubMed ID: 17987533 [TBL] [Abstract][Full Text] [Related]
13. [The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer]. Daniltchenko D; Riedl C; Koenig F; Daha LK; Sachs M; Schnorr D Aktuelle Urol; 2004 Nov; 35(6):497-501. PubMed ID: 15526230 [TBL] [Abstract][Full Text] [Related]
14. Blue-sky thinking about blue-light cystoscopy. Thomas K; O'Brien T BJU Int; 2009 Oct; 104(7):887-9. PubMed ID: 19583718 [No Abstract] [Full Text] [Related]
15. Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305). Mostafid H; Bunce C; BJU Int; 2009 Oct; 104(7):889-90. PubMed ID: 19549121 [No Abstract] [Full Text] [Related]
16. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669 [TBL] [Abstract][Full Text] [Related]
17. Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid. Drăgoescu O; Tomescu P; Pănuş A; Enache M; Maria C; Stoica L; Pleşea IE Rom J Morphol Embryol; 2011; 52(1):123-7. PubMed ID: 21424043 [TBL] [Abstract][Full Text] [Related]
18. The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer. Bunce C; Ayres BE; Griffiths TR; Mostafid H; Kelly J; Persad R; Kockelbergh R BJU Int; 2010 Feb; 105 Suppl 2():2-7. PubMed ID: 20089091 [No Abstract] [Full Text] [Related]
19. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Loidl W; Schmidbauer J; Susani M; Marberger M Eur Urol; 2005 Mar; 47(3):323-6. PubMed ID: 15716195 [TBL] [Abstract][Full Text] [Related]
20. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer. Yang LP Mol Diagn Ther; 2014 Feb; 18(1):105-16. PubMed ID: 24248555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]